These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

175 related items for PubMed ID: 35640957

  • 1. Identification of Infigratinib as a Potent Reversible Inhibitor and Mechanism-Based Inactivator of CYP2J2: Nascent Evidence for a Potential In Vivo Metabolic Drug-Drug Interaction with Rivaroxaban.
    Tang LWT, Wu G, Chan ECY.
    J Pharmacol Exp Ther; 2022 Aug; 382(2):123-134. PubMed ID: 35640957
    [Abstract] [Full Text] [Related]

  • 2. Infigratinib Is a Reversible Inhibitor and Mechanism-Based Inactivator of Cytochrome P450 3A4.
    Tang LWT, Teng JW, Verma RK, Koh SK, Zhou L, Go ML, Fan H, Chan ECY.
    Drug Metab Dispos; 2021 Sep; 49(9):856-868. PubMed ID: 34326139
    [Abstract] [Full Text] [Related]

  • 3. Application of Static Modeling --in the Prediction of In Vivo Drug-Drug Interactions between Rivaroxaban and Antiarrhythmic Agents Based on In Vitro Inhibition Studies.
    Cheong EJ, Goh JJ, Hong Y, Venkatesan G, Liu Y, Chiu GN, Kojodjojo P, Chan EC.
    Drug Metab Dispos; 2017 Mar; 45(3):260-268. PubMed ID: 28053220
    [Abstract] [Full Text] [Related]

  • 4. Identifying the Dominant Contribution of Human Cytochrome P450 2J2 to the Metabolism of Rivaroxaban, an Oral Anticoagulant.
    Zhao T, Chen Y, Wang D, Wang L, Dong P, Zhao S, Wang C, Meng Q, Sun H, Liu K, Wu J.
    Cardiovasc Drugs Ther; 2022 Feb; 36(1):121-129. PubMed ID: 33411110
    [Abstract] [Full Text] [Related]

  • 5. Direct and Sequential Bioactivation of Pemigatinib to Reactive Iminium Ion Intermediates Culminates in Mechanism-Based Inactivation of Cytochrome P450 3A.
    Tang LWT, Wei W, Verma RK, Koh SK, Zhou L, Fan H, Chan ECY.
    Drug Metab Dispos; 2022 May; 50(5):529-540. PubMed ID: 35153194
    [Abstract] [Full Text] [Related]

  • 6. Inhibition of Cytochrome P450 2J2-Mediated Metabolism of Rivaroxaban and Arachidonic Acid by Ibrutinib and Osimertinib.
    Wang Z, Yong Chan EC.
    Drug Metab Dispos; 2022 Oct; 50(10):1332-1341. PubMed ID: 35817438
    [Abstract] [Full Text] [Related]

  • 7. Metabolic Activation of the Acrylamide Michael Acceptor Warhead in Futibatinib to an Epoxide Intermediate Engenders Covalent Inactivation of CYP3A.
    Tang LWT, Fu J, Koh SK, Wu G, Zhou L, Chan ECY.
    Drug Metab Dispos; 2022 Jul; 50(7):931-941. PubMed ID: 35512804
    [Abstract] [Full Text] [Related]

  • 8. Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects.
    Mueck W, Kubitza D, Becka M.
    Br J Clin Pharmacol; 2013 Sep; 76(3):455-66. PubMed ID: 23305158
    [Abstract] [Full Text] [Related]

  • 9. Multiple modes of inhibition of human cytochrome P450 2J2 by dronedarone, amiodarone and their active metabolites.
    Karkhanis A, Lam HY, Venkatesan G, Koh SK, Chai CL, Zhou L, Hong Y, Kojodjojo P, Chan EC.
    Biochem Pharmacol; 2016 May 01; 107():67-80. PubMed ID: 26972388
    [Abstract] [Full Text] [Related]

  • 10. Mechanism-Based Inactivation of Cytochrome P450 3A4 by Benzbromarone.
    Tang LWT, Verma RK, Fan H, Chan ECY.
    Mol Pharmacol; 2021 Apr 01; 99(4):266-276. PubMed ID: 33436520
    [Abstract] [Full Text] [Related]

  • 11. Mechanism-Based Inactivation of Cytochrome P450 3A4 and 3A5 by the Fibroblast Growth Factor Receptor Inhibitor Erdafitinib.
    Tang LWT, Teng JW, Koh SK, Zhou L, Go ML, Chan ECY.
    Chem Res Toxicol; 2021 Jul 19; 34(7):1800-1813. PubMed ID: 34189909
    [Abstract] [Full Text] [Related]

  • 12. Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.
    Lee CA, Jones JP, Katayama J, Kaspera R, Jiang Y, Freiwald S, Smith E, Walker GS, Totah RA.
    Drug Metab Dispos; 2012 May 19; 40(5):943-51. PubMed ID: 22328583
    [Abstract] [Full Text] [Related]

  • 13. Application of a physiologically based pharmacokinetic model of rivaroxaban to prospective simulations of drug-drug-disease interactions with protein kinase inhibitors in cancer-associated venous thromboembolism.
    Cheong EJY, Ng DZW, Chin SY, Wang Z, Chan ECY.
    Br J Clin Pharmacol; 2022 May 19; 88(5):2267-2283. PubMed ID: 34837258
    [Abstract] [Full Text] [Related]

  • 14. Differential Reversible and Irreversible Interactions between Benzbromarone and Human Cytochrome P450s 3A4 and 3A5.
    Tang LWT, Verma RK, Yong RP, Li X, Wang L, Lin Q, Fan H, Chan ECY.
    Mol Pharmacol; 2021 Sep 19; 100(3):224-236. PubMed ID: 34210765
    [Abstract] [Full Text] [Related]

  • 15. Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs.
    Zhou S, Yung Chan S, Cher Goh B, Chan E, Duan W, Huang M, McLeod HL.
    Clin Pharmacokinet; 2005 Sep 19; 44(3):279-304. PubMed ID: 15762770
    [Abstract] [Full Text] [Related]

  • 16. Development and verification of a physiologically based pharmacokinetic model of dronedarone and its active metabolite N-desbutyldronedarone: Application to prospective simulation of complex drug-drug interaction with rivaroxaban.
    Leow JWH, Ang XJ, Chan ECY.
    Br J Clin Pharmacol; 2023 Jun 19; 89(6):1873-1890. PubMed ID: 36683488
    [Abstract] [Full Text] [Related]

  • 17. Mechanism-based inactivation of cytochrome P-450-3A4 by mifepristone (RU486).
    He K, Woolf TF, Hollenberg PF.
    J Pharmacol Exp Ther; 1999 Feb 19; 288(2):791-7. PubMed ID: 9918590
    [Abstract] [Full Text] [Related]

  • 18. Risk assessment and molecular mechanism study of drug-drug interactions between rivaroxaban and tyrosine kinase inhibitors mediated by CYP2J2/3A4 and BCRP/P-gp.
    Zhao T, Li X, Chen Y, Du J, Chen X, Wang D, Wang L, Zhao S, Wang C, Meng Q, Sun H, Liu K, Wu J.
    Front Pharmacol; 2022 Feb 19; 13():914842. PubMed ID: 36071847
    [Abstract] [Full Text] [Related]

  • 19. Inactivation of Human Cytochrome P450 3A4 and 3A5 by Dronedarone and N-Desbutyl Dronedarone.
    Hong Y, Chia YM, Yeo RH, Venkatesan G, Koh SK, Chai CL, Zhou L, Kojodjojo P, Chan EC.
    Mol Pharmacol; 2016 Jan 19; 89(1):1-13. PubMed ID: 26490246
    [Abstract] [Full Text] [Related]

  • 20. Predicting drug-drug interactions with physiologically based pharmacokinetic/pharmacodynamic modelling and optimal dosing of apixaban and rivaroxaban with dronedarone co-administration.
    Wen HN, He QF, Xiang XQ, Jiao Z, Yu JG.
    Thromb Res; 2022 Oct 19; 218():24-34. PubMed ID: 35985100
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.